Analysts Offer Insights on Healthcare Companies: Lemaitre Vascular (LMAT), Henry Schein (HSIC) and Exelixis (EXEL)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Lemaitre Vascular (LMAT), Henry Schein (HSIC) and Exelixis (EXEL).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lemaitre Vascular (LMAT)
KeyBanc analyst Brett Fishbin maintained a Hold rating on Lemaitre Vascular today. The company’s shares closed last Tuesday at $112.00.
According to TipRanks.com, Fishbin is ranked 0 out of 5 stars with an average return of
Lemaitre Vascular has an analyst consensus of Strong Buy, with a price target consensus of $111.86.
See the top stocks recommended by analysts >>
Henry Schein (HSIC)
In a report released today, Glen Santangelo from Barclays maintained a Buy rating on Henry Schein, with a price target of $86.00. The company’s shares closed last Tuesday at $74.37.
According to TipRanks.com, Santangelo is a 4-star analyst with an average return of
Currently, the analyst consensus on Henry Schein is a Moderate Buy with an average price target of $89.00, which is a 24.5% upside from current levels. In a report issued on May 4, Piper Sandler also maintained a Buy rating on the stock with a $99.00 price target.
Exelixis (EXEL)
In a report released today, Etzer Darout from Barclays maintained a Hold rating on Exelixis, with a price target of $45.00. The company’s shares closed last Tuesday at $44.42.
According to TipRanks.com, Darout is a 5-star analyst with an average return of
Currently, the analyst consensus on Exelixis is a Moderate Buy with an average price target of $47.55, a 7.0% upside from current levels. In a report issued on April 27, Oppenheimer also assigned a Hold rating to the stock.
Read More on LMAT:
